Clinical trials: Thymic Carcinoma, open to volunteers
Neuroendocrine Carcinoma of Lung, Neuroendocrine Carcinoma of Thymus
CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
The study involves the enrollment of 34 patients diagnosed with advanced thymic, pulmonary and duodeno-pancreatic well-differentiated high grade neuroendocrine tumors (Ki-67 > 20%).
- Trial name
- LINEAR (NCT07429851)
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- European Institute of Oncology
Mesothelioma, Neoplasms
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs.
- Conditions
- Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT06885697
- Testing
- cyclophosphamide, fludarabine, TNhYP218 CAR T Cells
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Thymic Carcinoma
Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma
The goal of this clinical trial (Phase II) is to evaluate the efficacy and safety of neoadjuvant Adebrelimab combined with chemoradiation in patients with locally advanced thymic carcinoma.
- Trial name
- NCT07479628
- Testing
- adebrelimab plus chemoradiation
- Volunteers
- 31 people
- Sponsor
- Shanghai Chest Hospital
Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin
An International Study on Pediatric Patients With Rare Tumors.
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
- Conditions
- Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin, Gastrointestinal Stromal Tumor (GIST), Adrenocortical Tumor
- Trial name
- PARTNER (NCT07072143)
- Where
- Italy
- Volunteers
- 6,250 people
- Sponsor
- Azienda Ospedaliera di Padova
Thymus Neoplasms, Thymic Epithelial Tumor
Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors
This is a multi-center, open-label, single-arm, prospective interventional study evaluating hypofractionated adjuvant radiotherapy (HART) after radical thymothymectomy in patients with thymic epithelial tumors.
- Conditions
- Thymus Neoplasms, Thymic Epithelial Tumor, Thymoma, Thymic Carcinoma
- Trial name
- THOR (NCT07693855)
- Testing
- Hypofractionated Adjuvant Proton Therapy, Hypofractionated Adjuvant Photon Radiation Therapy
- Where
- 3 sites in Taiwan
- Volunteers
- 69 people
- Sponsor
- National Taiwan University Hospital
Thymoma and Thymic Carcinoma, Pleural Metastasis
Phase II Trial of Hypofractionated Radiotherapy Guided by Optical Surface Imaging and Fan-beam CT for Thymoma With Pleural Metastasis
This trial plans to conduct a prospective, randomized controlled phase II clinical study to explore the efficacy and safety of hypofractionated radiotherapy guided by optical surface imaging combined with FBCT in patients with…
- Trial name
- NCT07879417
- Testing
- hypofractionated radiotherapy guided by optical surface imaging and FBCT, hypofractionated radiotherapy guided by CBCT
- Volunteers
- 234 people
- Sponsor
- Sun Yat-sen University
Thymoma, Thymic Carcinoma
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
The goal of this clinical trial is to study the effect of sacituzumab govitecan-hziy in adult patients with advanced thymoma and thymic carcinoma after progressing on at least one prior line of therapy.
- Trial name
- NCT06248515
- Testing
- Sacituzumab govitecan-hziy
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Georgetown University
NSCLC, Non-Small Cell Lung Cancer
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
Background: Immunotherapy is a type of treatment that works by making the body s own immune system stronger. These treatments are used for cancers such as non small cell lung cancer (NSCLC); thymic carcinoma (TC); or metastatic…
- Conditions
- NSCLC, Non-Small Cell Lung Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT07902921
- Testing
- STAR0602, Nivolumab
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Cancer Institute (NCI)
Thymoma and Thymic Carcinoma
6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
This randomized controlled trial compares 6 versus 3 cycles of neoadjuvant chemotherapy in patients with potentially resectable locally advanced thymic epithelial tumors (TETs, WHO type AB/B/C, AJCC TNM stage IIIA-IVA).
- Trial name
- NCT07463313
- Testing
- Cyclophosphamide, Doxorubicin, and Cisplatin (CAP), nab-Paclitaxel and Carboplatin
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Thymic Carcinoma, Thymoma
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
It is an open-lable, single-arm, single-center, phase II clinical trial conducted in China, and plan to recruiting 20 patients who were progressed after first line chemotherapy or chemotherapy combined with immunotherapy.
- Trial name
- NCT06838910
- Testing
- Experimental: tislelizumab+anlotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Thymic Epithelial Tumor, Thymic Carcinoma
Molecular Analysis and Treatment Options of Thymic Malignancies
Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death.
- Conditions
- Thymic Epithelial Tumor, Thymic Carcinoma, Thymic Cancer
- Trial name
- NCT05667948
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital
Adrenal Cortical Carcinoma, Medullary Thyroid Cancer
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
Treatment of advanced endocrine tumors, including adrenal corticocarcnioma (ACC), medullary thyroid carcinoma (MTC), thymic neuroendocrine tumor and pancreatic neuroendocrine tumor is challenging.
- Conditions
- Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT06141369
- Testing
- individualized mRNA neoantigen vaccine (mRNA-0523-L001)
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Thymic Epithelial Tumor, Thymoma
Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis
The goal of this observational study is to explore the effectiveness of electrocautery resection combined with hyperthermic intrathoracic chemotherapy (HITHOC) in patients with thymic epithelial tumors with pleural metastasis or…
- Conditions
- Thymic Epithelial Tumor, Thymoma, Thymic Carcinoma, Pleural Metastasis
- Trial name
- NCT07328074
- Testing
- Patients with thymic epithelial tumors with pleural metastasis or recurrence who undergo extended thymectomy with electrocautery resection of pleural metastases followed by two cycles of hyperthermic, Hyperthermic Intrathoracic Chemotherapy (HITHOC)
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Thymoma and Thymic Carcinoma, Thymoma
Hypofractionated Radiotherapy for Thymic Epithelial Tumors
The goal of this clinical trial is to learn if hypofractionated radiotherapy works to shorten the treatment time without increasing the side effects in patients of thymic epithelial tumors.
- Conditions
- Thymoma and Thymic Carcinoma, Thymoma, Thymic Cancer, Thymic Epithelial Tumor
- Trial name
- NCT06692062
- Testing
- Hypofractionated Radiation Therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Rongrong Zhou
Thymic Carcinoma
Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
The goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are: 1.
- Trial name
- NCT06402708
- Testing
- Chemotherapy, Radiotherapy
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Fudan University
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced…
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07006727
- Testing
- 225Ac-ETN029, 111In-ETN029
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Stage III Thymoma AJCC v8, Stage IIIA Thymoma AJCC v8
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
This phase I trial studies the sides effects and best dose of pembrolizumab in treating participants with thymoma or thymic cancer that cannot be removed by surgery.
- Conditions
- Stage III Thymoma AJCC v8, Stage IIIA Thymoma AJCC v8, Stage IIIB Thymoma AJCC v8, Stage IV Thymoma AJCC v8
- Trial name
- NCT03295227
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Thymus Carcinoma
Ivonescimab for the Treatment of Thymic Cancer
This phase II trial tests how well ivonescimab works in treating patients with thymic carcinoma. Immunotherapy with monoclonal antibodies, such as ivonescimab, may help the body's immune system attack the cancer, and may…
- Trial name
- NCT06980077
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Thymic Epithelial Tumor, Recurrent Thymoma
PT-112 in Subjects With Thymoma and Thymic Carcinoma
Background: There are no approved drugs to treat recurrent thymoma and thymic carcinoma. New therapies are needed for people with these cancers. Researchers want to see if the drug PT-112 can help. PT-112 kills cancer cells.
- Conditions
- Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer
- Trial name
- NCT05104736
- Testing
- PT-112
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Untreated Advanced or Recurrent Thymic Carcinomas
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
A phase II, investigator-initiated, non-randomized, open-label, single-arm, multicenter study to evaluate the efficacy and safety of Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab combination for previously untreated advanced or…
- Trial name
- Artemis (NCT05832827)
- Testing
- MK-3475, Lenvatinib, Carboplatin
- Where
- Japan
- Volunteers
- 35 people
- Sponsor
- National Cancer Center, Japan